DK2525827T3 - Farmaceutiske formuleringer af loratadin til indkapsling og kombinationer deraf - Google Patents

Farmaceutiske formuleringer af loratadin til indkapsling og kombinationer deraf Download PDF

Info

Publication number
DK2525827T3
DK2525827T3 DK11734280.8T DK11734280T DK2525827T3 DK 2525827 T3 DK2525827 T3 DK 2525827T3 DK 11734280 T DK11734280 T DK 11734280T DK 2525827 T3 DK2525827 T3 DK 2525827T3
Authority
DK
Denmark
Prior art keywords
loratadine
encapsulation
combinations
pharmaceutical formulations
formulations
Prior art date
Application number
DK11734280.8T
Other languages
English (en)
Inventor
Peter Draper
James Draper
Beth Okutan
Original Assignee
Catalent Ontario Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catalent Ontario Ltd filed Critical Catalent Ontario Ltd
Application granted granted Critical
Publication of DK2525827T3 publication Critical patent/DK2525827T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK11734280.8T 2010-01-19 2011-01-18 Farmaceutiske formuleringer af loratadin til indkapsling og kombinationer deraf DK2525827T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA2690490A CA2690490C (en) 2010-01-19 2010-01-19 Pharmaceutical formulations of loratadine for encapsulation and combinations thereof
PCT/CA2011/000052 WO2011088550A1 (en) 2010-01-19 2011-01-18 Pharmaceutical formulations of loratadine for encapsulation and combinations thereof

Publications (1)

Publication Number Publication Date
DK2525827T3 true DK2525827T3 (da) 2020-12-14

Family

ID=44303619

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11734280.8T DK2525827T3 (da) 2010-01-19 2011-01-18 Farmaceutiske formuleringer af loratadin til indkapsling og kombinationer deraf

Country Status (17)

Country Link
US (1) US20120301544A1 (da)
EP (2) EP3653204A1 (da)
JP (1) JP5328992B2 (da)
AU (1) AU2011207058B2 (da)
CA (1) CA2690490C (da)
CY (1) CY1123895T1 (da)
DK (1) DK2525827T3 (da)
ES (1) ES2843351T3 (da)
HR (1) HRP20201923T1 (da)
HU (1) HUE053412T2 (da)
LT (1) LT2525827T (da)
MX (1) MX344163B (da)
PL (1) PL2525827T3 (da)
PT (1) PT2525827T (da)
RS (1) RS61362B1 (da)
SI (1) SI2525827T1 (da)
WO (1) WO2011088550A1 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103784399B (zh) * 2014-03-05 2015-09-30 大连金石滩药业有限公司 氯雷他定液体组合物
CN103784446B (zh) * 2014-03-05 2016-01-06 大连金石滩药业有限公司 氯雷他定组合物
JP7065562B2 (ja) * 2015-09-04 2022-05-12 ロート製薬株式会社 医薬組成物
KR101746500B1 (ko) 2016-05-26 2017-06-14 (주)알피바이오 연질캡슐 제제용 로라타딘 조성물 및 이를 함유하는 연질캡슐
US11607384B2 (en) 2017-12-08 2023-03-21 Western University Of Health Sciences Lipid emulsified drug delivery systems for chemoprevention and treatment
MX2020012233A (es) 2018-05-16 2021-01-29 Bayer Healthcare Llc Formula de suspension de alta concentracion para medicamentos en capsula de gel blanda para resfriado y gripe.
CN112426404B (zh) * 2020-10-29 2023-02-28 太阳升(亳州)生物医药科技有限公司 用于制备富马酸卢帕他定口服液的方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4282233B1 (en) 1980-06-19 2000-09-05 Schering Corp Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines
AU570306B2 (en) 1984-02-15 1988-03-10 Schering Corporation 8-chloro-6, 11-dihydro-11-(4-piperidylidene)-5h-benzo (5,6) cyclohepta (1,2-b) pyridine and its salts.
GB8903804D0 (en) * 1989-02-20 1989-04-05 Sandoz Ltd Improvements in or relating to organic compounds
US4910205A (en) 1988-05-02 1990-03-20 Schering Corporation Transdermal delivery of loratadine
US4863931A (en) 1988-09-15 1989-09-05 Schering Corporation Antihistaminic fluoro substituted benzocycloheptapyridines
US4990535A (en) 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
ZA925581B (en) * 1991-07-26 1993-05-14 Smithkline Beecham Corp Pharmaceutical microemulsions.
US5314697A (en) 1992-10-23 1994-05-24 Schering Corporation Stable extended release oral dosage composition comprising loratadine and pseudoephedrine
GB9226238D0 (en) 1992-12-16 1993-02-10 Scherer Ltd R P Encapsulation apparatus and process
US6054136A (en) * 1993-09-30 2000-04-25 Gattefosse S.A. Orally administrable composition capable of providing enhanced bioavailability when ingested
CA2181241C (en) * 1994-01-24 2000-04-25 Dadi Jamshed Dhabhar Process for solubilizing difficultly soluble pharmaceutical actives
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
NZ284068A (en) * 1994-04-07 1998-06-26 Smithkline Beecham Plc Medicament comprising halofantrine free base
US5595997A (en) 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
EP1049459B1 (en) * 1998-01-20 2009-04-22 Applied Analytical Industries, Inc. Oral liquid compositions
US6132758A (en) 1998-06-01 2000-10-17 Schering Corporation Stabilized antihistamine syrup
ATE274907T1 (de) 1998-06-30 2004-09-15 Pfizer Prod Inc Loratadin zur verwendung als antiarrhythmikum
US6221391B1 (en) * 1998-11-23 2001-04-24 Accucaps Industries Limited Self-emulsifying ibuprofen solution and soft gelatin capsule for use therewith
US20030235595A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent
US6720002B2 (en) 2001-07-20 2004-04-13 R.P. Scherer Technologies, Inc. Antihistamine formulations for soft capsule dosage forms
ES2294197T3 (es) * 2001-12-21 2008-04-01 Supernus Pharmaceuticals, Inc. Formulacion de capsula oral con estabilidad fisica aumentada.
US20040033257A1 (en) * 2002-05-30 2004-02-19 Strides Inc. Pharmaceutical formulation in a drug delivery system and process for preparing the same
KR100533460B1 (ko) * 2002-07-20 2005-12-08 대화제약 주식회사 난용성 약물의 가용화용 점막흡착성 조성물, 이를 이용한난용성 약물의 가용화용 제형 및 이들의 제조 방법
RU2007139819A (ru) * 2005-03-29 2009-05-10 МакНЕЙЛ-Пи-Пи-Си, ИНК. (US) Композиции с гидрофильными лекарствами в гидрофобной среде
US20110020440A1 (en) * 2007-11-19 2011-01-27 Cadila Pharmaceuticals Limited Stable solutions of sparingly soluble actives

Also Published As

Publication number Publication date
ES2843351T3 (es) 2021-07-16
EP3653204A1 (en) 2020-05-20
PT2525827T (pt) 2021-01-20
HRP20201923T1 (hr) 2021-02-05
CY1123895T1 (el) 2022-05-27
EP2525827B1 (en) 2020-11-18
LT2525827T (lt) 2021-03-25
US20120301544A1 (en) 2012-11-29
SI2525827T1 (sl) 2021-02-26
CA2690490C (en) 2012-06-26
RS61362B1 (sr) 2021-02-26
CA2690490A1 (en) 2011-07-19
WO2011088550A1 (en) 2011-07-28
AU2011207058B2 (en) 2015-04-23
JP2013517303A (ja) 2013-05-16
HUE053412T2 (hu) 2021-06-28
JP5328992B2 (ja) 2013-10-30
MX344163B (es) 2016-12-07
MX2012008301A (es) 2012-09-28
EP2525827A1 (en) 2012-11-28
PL2525827T3 (pl) 2021-05-04
AU2011207058A1 (en) 2012-09-06
EP2525827A4 (en) 2014-04-30

Similar Documents

Publication Publication Date Title
DK2648742T3 (da) Formuleringer indeholdende saponiner og anvendelser deraf
SMT201700008B (it) Composizione farmaceutica
DK3622883T3 (da) Indførerer til medicinsk indretning og fremgangsmåder til at indføre og anvende medicinske indretninger
DK2498756T3 (da) Tabletformuleringer af neratinibmaleat
DK3527241T3 (da) Indretning til administration af lægemiddel
DK3278665T3 (da) Stabil farmaceutisk sammensætning og fremgangsmåder til anvendelse deraf
DK3284467T3 (da) Nikotinholdige farmaceutiske sammensætninger
DK2558133T3 (da) Coatinger til fremstillingen og anvendelse af polyhydroxyalkanoat-lægemiddelindretninger
DK3626258T3 (da) Fremgangsmåder og sammensætninger til cns-levering af iduronat-2-sulfatase
DK3158991T3 (da) Formuleringer af bendamustin
DK2428450T3 (da) Doseringsmetode og doseringsindretning
DK2632954T4 (da) Midler og fremgangsmåder til behandling af dlbcl
DK3378862T3 (da) Dihydropyrimidinoisoquinolinoner og farmaceutiske sammensætninger deraf til behandlingen af multipel sklerose
DK3246018T3 (da) Farmaceutisk sammensætning
DK2729151T3 (da) Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf
DK2593463T3 (da) Formuleringer af rifaximin og anvendelser deraf
GT201200303A (es) Formulaciones farmacéuticas
SMT201400069B (it) Formulazione farmaceutica
DK2600715T3 (da) Flydende ST-246-formuleringer og fremgangsmåder
DK3011975T3 (da) Faststofsammensætning til oral administration af farvestoffer og diagnostisk anvendelse deraf
DK2654736T3 (da) Hidtil ukendt farmaceutisk sammensætning
DK2525789T3 (da) Farmaceutiske formuleringer af naproxen til softgel-indkapsling og kombinationer deraf
ITTO20110641A1 (it) Composizioni farmaceutiche e metodi di trattamento
DK2525827T3 (da) Farmaceutiske formuleringer af loratadin til indkapsling og kombinationer deraf
DK2475649T3 (da) Indenonderivat og farmaceutisk sammensætning omfattende samme